RS-2023-00258721

# TC011: Clinical Phase I Trial Evaluating Safety, Pharmacokinetics, DLT, MTD, Efficacy and RP2D of TC011, a CD19-Targeted CAR-T Therapyin Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Patients

TICAROS

THERAPEUTICS TICAROS

**ONCOLOGY** | **Phase 1**

| | |
|---|---|
| Product Type | Gene-modified Chimeric Antigen Receptor T-Cell (CAR-T) |
| Indication | B-Cell Non-Hodgkin Lymphoma |
| Target | Cluster of Differentiation 19 (CD19) |
| MoA(Mechanism of Action) | CD19-specific Targeting CAR-T Cells Bind to Tumor Cells → Proprietary T cell-Strengthened, Gene Modified CAR-T Cells Eliminate Tumor Cells with Augmented Efficacy → Enhanced CAR-T Cell Therapy Achieved through Substitution of the CAR-T Cell Transmembrane Backbone, Leveraging Immune Synapse Potentiation Characteristics of Mol-X. |
| Competitiveness | • TiCARos utilizes CLIP (Clamping-based Immunological Synapse Potentiating) CAR technology which potentiates immune synapse by modification of transmembrane backbone of CAR-T Cell.<br>• As immune synapse potentiating module, it allows T cells to have tighter, wider and more advantageous immune synapse surface for T cells to carry our its therapeutic activity<br>• Since it does not participate in modification of extracellular binding domain nor intracellular signaling domain, there is no possibility of mechanism manipulation – making CLIP simpler and safter way to modify CAR-T Cells |
| Development Stage | Phase 1 |
| Route of Administration | Parenteral-Intravenous |

kddf_bd@kddf.org
KDDF Business Development Team

KDDF Korea Drug Development Fund